Products
| Product | Strength | Pack Size |
|---|---|---|
| Anastrozole Tablets | 1mg | 100 tablets / box |
| Capecitabine Tablets | 150mg | 60 tablets / box |
| Capecitabine Tablets | 500mg | 120 tablets / box |
| Docetaxel Concentrate for Solution for Infusion | 20mg/1ml | 1 vial / box |
| Docetaxel Concentrate for Solution for Infusion | 80mg/4ml | 1 vial / box |
| Docetaxel Concentrate for Solution for Infusion | 160mg/8ml | 1 vial / box |
| Gemcitabine Powder for Solution for Infusion | 200mg | 1 vial / box |
| Gemcitabine Powder for Solution for Infusion | 1g | 1 vial / box |
| Letrozole Tablets | 2.5mg | 120 tablets / box |
* The above product list shows our products which are approved by Hong Kong Department of Health only. It does not mean that all products are already placed in the market. For any product or business enquiries please contact us at ichk@ichk.org or (852) 2891 0581 for further details.
Breast Cancer
Breast cancer is the most common cancer among women. The number of female breast cancer cases diagnosed in Hong Kong has increased by 3.8 times between 1993 and 2017. Risk factors associated with breast cancer include lack of exercise, obesity and high level of stress. In addition to surgery, different pharmacological treatments are available for breast cancer, including hormone therapy and chemotherapy.
Hormone therapy
Aromatase inhibitors (e.g. Letrozole, Anastrozole) inhibit the production of estrogen in peripheral tissues in post-menopausal women. They are the first-line treatment options for post-menopausal women with estrogen receptor-positive breast cancer, which are shown to be more effective than Tamoxifen. Letrozole and Anastrozole share similar clinical outcomes and tolerability. Individual patients may tolerate one of these agents better than the other and it is reasonable to switch to an alternative aromatase inhibitor if the initial one is poorly tolerated.
Selective estrogen receptor modulators (SERMs) act as an estrogen antagonist in the breasts but estrogen agonist in the bones, blood and uterus. Tamoxifen is indicated in both pre-menopausal and post-menopausal women with estrogen receptor-positive breast cancer. Due to its different effects in various tissues, it has a lower risk of osteoporosis than aromatase inhibitors but a higher risk of serious complications such as thromboembolism and endometrial cancer.
Chemotherapy
Taxanes (e.g. Paclitaxel, Docetaxel) are often used in combination with anthracyclines and cyclophosphamide as the initial chemotherapy. It has been shown that the addition of taxanes produces a significantly better median time to progression and overall survival, while decreasing cardiotoxicity due to reduced dosage of anthracyclines. Taxanes are also the first-line treatment of metastatic breast cancer. Antimetabolites (e.g. Capecitabine, Gemcitabine) can be used in combination with taxanes after the failure of anthracycline-based chemotherapy.
Hormone therapy
Aromatase inhibitors (e.g. Letrozole, Anastrozole) inhibit the production of estrogen in peripheral tissues in post-menopausal women. They are the first-line treatment options for post-menopausal women with estrogen receptor-positive breast cancer, which are shown to be more effective than Tamoxifen. Letrozole and Anastrozole share similar clinical outcomes and tolerability. Individual patients may tolerate one of these agents better than the other and it is reasonable to switch to an alternative aromatase inhibitor if the initial one is poorly tolerated.
Selective estrogen receptor modulators (SERMs) act as an estrogen antagonist in the breasts but estrogen agonist in the bones, blood and uterus. Tamoxifen is indicated in both pre-menopausal and post-menopausal women with estrogen receptor-positive breast cancer. Due to its different effects in various tissues, it has a lower risk of osteoporosis than aromatase inhibitors but a higher risk of serious complications such as thromboembolism and endometrial cancer.
Chemotherapy
Taxanes (e.g. Paclitaxel, Docetaxel) are often used in combination with anthracyclines and cyclophosphamide as the initial chemotherapy. It has been shown that the addition of taxanes produces a significantly better median time to progression and overall survival, while decreasing cardiotoxicity due to reduced dosage of anthracyclines. Taxanes are also the first-line treatment of metastatic breast cancer. Antimetabolites (e.g. Capecitabine, Gemcitabine) can be used in combination with taxanes after the failure of anthracycline-based chemotherapy.